Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Chugai Pharmaceutical Co Ltd
XMUN:CUP
|
JP |
|
Katitas Co Ltd
OTC:KTITF
|
JP |
|
D
|
DLP Resources Inc
OTC:DLPRF
|
CA |
|
Intellicheck Inc
F:J5L1
|
US |
Chugai's multi-year record shows sustained revenue and profit growth with operating margins expanding as product and royalty income scale. It funds substantial R&D internally and retains a debt-light, liquid balance sheet, although recent investment spending has become more prominent in cash deployment.
The quarter ended June 30, 2026 extended the established growth and profitability pattern, while the December 31, 2025 cash-flow data showed a material step-up in capital spending that reduced free-cash-flow conversion without making free cash flow negative. Earnings momentum remains intact, but cash deployment is becoming more investment-led.
Whether operating cash flow normalizes while capital spending remains elevated and free-cash-flow conversion recovers.
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 491.8B | 534.2B | 579.8B | 686.2B | 786.9B | 999.8B | 1.3T | 1.1T | 1.2T | 1.3T | |
| (247.9B) | (254.2B) | (262.8B) | (264.7B) | (273.5B) | (337.7B) | (476.3B) | (412.7B) | (337.9B) | (352.9B) | |
| 243.8B | 280B | 316.9B | 421.5B | 513.5B | 662.1B | 783.5B | 698.7B | 832.8B | 905.1B | |
| (167B) | (181.1B) | (192.6B) | (206.9B) | (211.3B) | (233.8B) | (249.5B) | (253.8B) | (285B) | (293.7B) | |
| (81.9B) | (88.1B) | (93.4B) | (100.7B) | (93B) | (100.8B) | (99.6B) | (111.9B) | (109.7B) | (116.3B) | |
| (85B) | (92.9B) | (99.2B) | (104.7B) | (116.6B) | (131.3B) | (148.1B) | (169.1B) | (176.7B) | (185.7B) | |
| — | — | — | (1.5B) | (1.7B) | (1.8B) | (1.8B) | (1.4B) | (818m) | (373m) | |
| (1m) | — | 1m | — | — | — | (63m) | 28.6B | 2.3B | 8.6B | |
| 76.9B | 98.9B | 124.3B | 214.5B | 302.2B | 428.2B | 534B | 444.9B | 547.8B | 611.4B | |
| 1.3B | 4m | 444m | 519m | (1.6B) | 56m | 769m | 4.2B | 323m | (3.4B) | |
| 8m | 5m | 5m | 27m | 34m | 48m | 58m | 81m | 94m | 425m | |
| (160m) | (97m) | — | (3.9B) | (953m) | (6.3B) | (641m) | (5.8B) | (5.8B) | (12.6B) | |
| (3.5B) | (1.8B) | (3.3B) | (3.2B) | (1.5B) | (2.6B) | (2.9B) | 407m | 709m | 2.3B | |
| 74.4B | 97B | 121.4B | 207.9B | 298.2B | 419.4B | 531.2B | 443.8B | 543B | 597.8B | |
| (20.1B) | (23.5B) | (28.4B) | (50.3B) | (83.5B) | (116.4B) | (156.7B) | (118.3B) | (155.7B) | (163.8B) | |
| 54.4B | 73.5B | 93.1B | 157.6B | 214.7B | 303B | 374.4B | 325.5B | 387.3B | 434B | |
| (780m) | (827m) | (591m) | — | — | — | — | — | — | — | |
| 53.6B | 72.7B | 92.5B | 157.6B | 214.7B | 303B | 374.4B | 325.5B | 387.3B | 434B | |
| 32.66 | 44.28 | 56.27 | 95.81 | 130.53 | 184.17 | 227.57 | 197.80 | 235.36 | 263.73 |
© 2026 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
AI-generated answers can contain mistakes, outdated facts, or incomplete information. Always verify important details before making decisions.
The AI Assistant is designed for research and education. It does not provide personalized investment, legal, or tax advice.
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more
